Page 78 - JCTR-11-1

Journal of Clinical and
Translational Research Pediatric dosing of antituberculosis medicines

2013;40:597-607. pharmacist’s dilemma. Contemp Pharm Pract. 1980;3:11-4.
doi: 10.1007/s10928-013-9332-2 30. Lack JA, Stuart-Taylor ME. Calculation of drug dosage
and body surface area of children. Br J Anaesth.
21. Cao Y, Jusko WJ. Applications of minimal physiologically- 1997;78(5):601-605.
based pharmacokinetic models. J Pharmacokinet
Pharmacodyn. 2012;39:711-723. doi: 10.1093/bja/78.5.601
doi: 10.1007/s10928-012-9280-2 31. Mahmood I. A simple method for the prediction of
therapeutic proteins (monoclonal and polyclonal antibodies
22. Björkman S. Reduction and lumping of physiologically based and non-antibody proteins) for first-in-pediatric dose
pharmacokinetic models: Prediction of the disposition of selection: Application of salisbury rule. Antibodies (Basel).
fentanyl and pethidine in humans by successively simplified 2022;11:66.
models. J Pharmacokinet Pharmacodyn. 2003;30:285-307.
doi: 10.3390/antib11040066
doi: 10.1023/a:1026194618660
32. Mahmood I. Application of allometric scaling and salisbury
23. Björkman S. Prediction of drug disposition in infants and rule for the prediction of antimalarial drugs for first-in-
children by means of physiologically based pharmacokinetic pediatric dose selection. Eur J Drug Metab Pharmacokinet.
(PBPK) modelling: Theophylline and midazolam as model 2023;48:587-594.
drugs. Br J Clin Pharmacol. 2004;59:691-704.
doi: 10.1007/s13318-023-00848-2
doi: 10.1111/j.1365-2125.2004.02225.x
33. Jing W, Zong Z, Tang B. Population pharmacokinetic analysis
24. Mahmood I, Tegenge MA. A comparative study of isoniazid among pulmonary tuberculosis patients from
between allometric scaling and physiologically based China. Antimicrob Agents Chemother. 2020;64:e01736-19.
pharmacokinetic modeling for the prediction of drug
clearance from neonates to adolescents. J Clin Pharmacol. doi: 10.1128/AAC.01736-19
2019;59:189-197. 34. Thomas L, Raju A, Sekhar C, et al. Influence of
doi: 10.1002/jcph.1310 N-acetyltransferase 2 (NAT2) genotype/single nucleotide
polymorphisms on clearance of isoniazid in tuberculosis
25. Mahmood I, Tegenge MA. Spreadsheet-based minimal patients: A systematic review of population pharmacokinetic
physiological models for the prediction of clearance of models. Eur J Clin Pharmacol. 2022;78:1535-1553.
therapeutic proteins in pediatric patients. J Clin Pharmacol.
2021;61:S108-S116. doi: 10.1007/s00228-022-03362-7
doi: 10.1002/jcph.1846 35. Box GE. Science and Statistics. J Am Stat Assoc.
1976;71:791-799.
26. Mahmood I. A comparison of different methods for the
first-in-pediatric dose selection. J Clin Transl Res. 2022; doi: 10.2307/2286841
8:369-81. 36. Mahmood I. Misconceptions and issues regarding allometric
27. Mahmood I, Ahmad T, Mansoor N, Sharib SM. Prediction scaling during the drug development process. Expert Opin
of clearance in neonates and infants (≤ 3 months of Drug Metab Toxicol. 2018;14:843-854.
age) for drugs that are glucuronidated: A comparative doi: 10.1080/17425255.2018.1499725
study between allometric scaling and physiologically
based pharmacokinetic modeling. J Clin Pharmacol. 37. Glazier DS. Variable metabolic scaling breaks the law:
2017;57:476-483. From ‘Newtonian’ to ‘Darwinian’ approaches. Proc Biol Sci.
2022;289:20221605.
doi: 10.1002/jcph.837
doi: 10.1098/rspb.2022.1605
28. Elias GP, Antoniali C, Mariano RC. Comparative study of 38. Valkengoed D, Krekels E, Knibbe C. All you need to know
rules employed for calculation of pediatric drug dosage. about allometric scaling: An integrative review on the
J Appl Oral Sci. 2005;13:114-119.
theoretical basis, empirical evidence, and application in
doi: 10.1590/s1678-77572005000200004 human pharmacology. Clin Pharmacokinet. 2024;64:173-192.
29. Munzenberger PJ, McKercher P. Pediatric dosing--the doi: 10.1007/s40262-024-01444-6

Volume 11 Issue 1 (2025) 72 doi: 10.36922/jctr.24.00070